Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 15/20 | 0.68 |
| ▸ | CCND1 | P24385 | 14/20 | 0.68 |
| ▸ | CDK1 | P06493 | 7/20 | 0.68 |
| ▸ | CCNB1 | P14635 | 7/20 | 0.68 |
| ▸ | CDK6 | Q00534 | 5/20 | 0.68 |
| ▸ | CDK2 | P24941 | 9/20 | 0.65 |
| ▸ | CCNA2 | P20248 | 6/20 | 0.65 |
| ▸ | CCNA1 | P78396 | 4/20 | 0.65 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.61 |
| ▸ | CCND3 | P30281 | 3/20 | 0.61 |
| ▸ | CDK7 | P50613 | 3/20 | 0.61 |
| ▸ | CDK9 | P50750 | 3/20 | 0.61 |
| ▸ | CCNH | P51946 | 3/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3548674 | 0.88 | CDK2 (0.80) | CDK4CCND1CDK1CCNB1CDK6 | |
| SCHEMBL4246771 | 0.86 | CDK4 (0.54) | CDK4CCND1CDK1CCNB1CDK6 | |
| SCHEMBL4254074 | 0.84 | CDK2 (0.81) | CDK4CCND1CDK1CCNB1CDK6 | |
| SCHEMBL4254071 | 0.84 | CDK2 (0.81) | CDK4CCND1CDK1CCNB1CDK6 | |
| SCHEMBL5380216 | 0.83 | CDK2 (0.72) | CDK4CCND1CDK1CCNB1CDK6 | |
| SCHEMBL4245323 | 0.83 | CDK4 (0.62) | CDK4CCND1CDK1CCNB1CDK6 | |
| SCHEMBL27701541 | 0.82 | CDK2 (0.62) | CDK4CCND1CDK1CCNB1CDK6 | |
| SCHEMBL2571663 | 0.79 | CDK4 (1.00) | CDK4CCND1CDK1CCNB1CDK6 | |
| Hydrochloric Acid SCHEMBL3549634 | 0.78 | CDK2 (0.59) | CDK4CCND1CDK1CCNB1CDK6 | |
| SCHEMBL4255289 | 0.78 | CDK2 (0.60) | CDK4CCND1CDK1CCNB1CDK6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233928-A1 | IMIDAZOLO-5-YL-2-ANILO-PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2009-09-17 | — | — | US | disclosed |
| EP-1869016-A1 | IMIDAZOLO-5-YL-2-ANILO-PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | AstraZeneca AB (SE) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006095159-A1 | (IMIDAZOLO-5-YL)-2-ANILO-PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2006-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233928-A1 | IMIDAZOLO-5-YL-2-ANILO-PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | MKI67, TYMP, PCNA | CDK4 30/4885CCND1 38/4885CDK1 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.